Shared care obesity management in 3-10 year old children: 12 month outcomes of HopSCOTCH randomised trial

Melissa Wake1, Kate Lycett, Susan A Clifford

  • 1Royal Children's Hospital, Parkville VIC 3052, Australia. melissa.wake@rch.org.au

BMJ (Clinical Research Ed.)
|June 12, 2013
PubMed

Insights

A shared care model for childhood obesity management in primary and tertiary settings was feasible and well-received but did not improve body mass index (BMI) or related outcomes compared to usual care. Improvements in BMI were observed in both groups, underscoring the importance of control groups in research.

Area of Science:

  • Pediatrics
  • Public Health
  • Clinical Trials

Background:

  • Childhood obesity is a significant public health concern requiring effective management strategies.
  • Integrated care models involving primary and tertiary settings are being explored to address this issue.
  • A shared care approach aims to leverage the strengths of both general practice and specialist weight management services.

Purpose of the Study:

  • To evaluate the effectiveness of a shared care model for managing obesity in children aged 3-10 years.
  • To determine if this model improves body mass index (BMI) and related health outcomes compared to usual care.
  • To assess the feasibility and acceptability of the shared care model for families and healthcare providers.

Main Methods:

  • A randomized controlled trial was conducted involving 22 family practices and a tertiary weight management service in Melbourne, Australia.
  • Children aged 3-10 years with obesity were randomly assigned to either the shared care intervention or usual care.
  • The intervention group received one tertiary appointment followed by general practice consultations over one year, supported by web-based software.

Main Results:

  • 107 children were analyzed (56 intervention, 51 control).
  • No significant difference in body mass index (BMI) z-score was found between the intervention and control groups at 15 months post-enrolment (adjusted mean difference -0.05; P=0.2).
  • No evidence of benefit or harm was observed for any secondary outcomes, including body fat percentage and quality of life.

Conclusions:

  • The shared care model, while feasible and highly rated, did not lead to improved BMI or other outcomes compared to usual care.
  • The study highlights the value of untreated control groups in accurately determining the efficacy of interventions.
  • Further research may be needed to optimize integrated care models for childhood obesity.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Documentation in Long-Term and Home Healthcare Setting01:29

Documentation in Long-Term and Home Healthcare Setting

Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Community Based Intervention01:30

Community Based Intervention

Community-based interventions in mental health represent a paradigm shift from institution-centered care to treatments embedded within the fabric of local communities. By prioritizing inclusion and leveraging existing societal structures, this approach fosters a supportive environment conducive to addressing mental health challenges while promoting individual dignity and agency.
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...